arrow
S

Spencer E. McMinn

Merck and Co.
H指数:9
被引数:302

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease (vol. 69, pg. 8548, 2026)

发现强效、选择性、中枢神经系统穿透性大环LRRK2抑制剂用于帕金森病的治疗(vol. 69, pg. 8548, 2026)

2026-04-010
PRE
Discovery of Potent; Selective; CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson’s Disease

发现强效、选择性、能穿透中枢神经系统的环状LRRK2抑制剂,用于帕金森病的治疗

2026-03-290
PRE
Discovery and In Vivo Evaluation of Aryl Ether YAP1/TEAD Inhibitors for the Treatment of Hippo-Driven Malignancies

芳基醚YAP1/TEAD抑制剂的发现及其在活体内的评估:用于治疗Hippo通路驱动的恶性肿瘤

2026-02-120
PRE
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors
2024-09-040
PRE
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease
2023-10-205
PRE
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease
2022-12-0712
PRE
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors
2021-12-3027
PREAI
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors
2021-10-139
OA
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy

合理设计的人精氨酸酶双环抑制剂的发现和优化,以增强癌症免疫治疗

2020-03-2321
OAAI